

SmartPA Criteria Proposal

Drug/Drug Class:	Glucagon Agents PDL Edit
First Implementation Date:	April 2, 2020
Proposed Date:	December 17, 2020
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Glucagon based products increase blood glucose levels during states of hypoglycemia by stimulating hepatic glucose receptors resulting in the breakdown of stored glycogen (glycogenolysis) and production and release of sugar from the liver (gluconeogenesis). Glucagon is reserved for patients in a severe hypoglycemic state with symptoms of disorientation, unconsciousness/unresponsiveness and seizures or convulsions. There are intranasal and injectable dosage forms available by prescription for the treatment of hypoglycemia. Route of administration of glucagon slightly differs in onset of action between intranasal and injectable products (13 minutes vs 16 minutes respectively), but the resolution of hypoglycemia occurs at around 30 minutes for both routes of administration.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Baqsimi™ GlucaGen HypoKit® Glucagon Kit (Eli Lilly) 	<ul style="list-style-type: none"> Glucagon Kit (Fresenius Kabi) Gvoke™

- Type of Criteria:**
- | | |
|--|---|
| <input type="checkbox"/> Increased risk of ADE | <input checked="" type="checkbox"/> Preferred Drug List |
| <input type="checkbox"/> Appropriate Indications | <input type="checkbox"/> Clinical Edit |
- Data Sources:**
- | | |
|--|--|
| <input type="checkbox"/> Only Administrative Databases | <input type="checkbox"/> Databases + Prescriber-Supplied |
|--|--|

Setting & Population

- Drug class for review: Glucagon Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents, with one being Baqsimi (defined as 1 claim each in the last 12 months):
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:

Progress Notes:

MedWatch Form:

Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

1. Evidence-Based Medicine and Fiscal Analysis: "Glucagon Products – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; October 2020.
2. Evidence-Based Medicine Analysis: "Glucagon Products", UMKC-DIC; November 2020.
3. Baqsimi (glucagon) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
4. Gvoke (glucagon) [package insert]. Chicago, IL: Xeris Pharmaceuticals, Inc.; 2019.
5. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2019.
6. USPDI, Micromedex; 2020.
7. Drug Facts and Comparisons On-line; 2020.

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.